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Abstract
The material world has been getting prone toward infectious diseases, and therefore 
novel strategies should be devised to treat chronic infectious disorders. The transla-
tional biomedical research scientists made early attempts to develop mouse-human 
chimera (humanized mouse) through the reconstitution of immunodeficient mouse 
with engraftment of human cells and tissues. Although the humanized mouse proved 
to be an effective tool in understanding various diseases such as human malaria and 
hepatitis, however, drug administration, retention capacity of the administered drug, 
toxicity, and ethical constraints are some of the major issues and need to be objectively 
addressed. The “humanization” of immunodeficient mouse needs pharmacological 
immunomodulatory reagents to control the excessively recruited cells of monocyte- 
macrophage lineage. Therefore, administration of liposome loaded with hydropho-
bic drug (clodronate) to induce selective apoptosis through “suicidal approach” in 
myeloid cells plays an instrumental role for controlling residual nonadaptive immune 
response of the host. Liposomes are spherical and hollow—structures consisting of lipid 
bilayer—and are used for the delivery of drug and vaccine candidates. The surface-
engineered liposomes (ligand anchored) are used for targeted and controlled delivery. 
Clodronate-loaded liposomes play a pivotal role in developing humanized mouse. This 
mouse holds relevance to study pathophysiology and immunopathology of  human 
malaria parasite, P. falciparum. The liposomal delivery of clodronate administered in 
immunodeficient mice to modulate their innate immune system is an amenable strategy 
with the minimal/acceptable range of systemic toxicity.
Keywords: humanized mouse, clodronate, liposomes, interleukin, immunity, innate 
response
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1. Mouse-human chimera(s)
A “humanized mouse” is an immunocompromised mouse carrying identical functions of cell 
or tissue in origin as seen in humans. The depletion of adaptive immune system allowed 
sizeable grafting of human cells to understand the biology and pathology of various diseases 
to developing therapeutic interventions. The nude and severe combined immunodeficiency 
(SCID) mouse have been used for the humanization, but recently the immunodeficient back-
ground of NOG/NSG mouse has shown significant receptivity toward the significant engraft-
ment and repopulation of human cells.
The need of immunodeficient mouse: An immunodeficient mouse is a laboratory mouse 
from a strain with a genetic mutation that causes a deteriorated or absent thymus, resulting 
in an inhibited immune system due to a greatly reduced number of T cells. The mouse is 
invaluable to translational research due to its susceptibility for different types of tissue and 
tumor grafts with less rejection episodes. These xenografts are commonly used in research to 
test new methods of imaging, treating tumors as well as understanding infectious diseases. 
The creation of a reproducible and straightforward animal model is inevitably required as it 
allows developing in-depth understanding on cellular and molecular mechanisms and patho-
physiological manifestation responsible for the cause of systemic inflammatory diseases.
1.1. Human-hepatocyte transplantation
The initial attempt made toward developing a human liver chimeric mouse was the one that 
would accept human hepatocytes. SCID/bg mouse with the urokinase-type plasminogen acti-
vator (uPA) gene linked to an albumin promoter was the first one to be developed. The immu-
nodeficient mice have subacute liver failure and are subjected to transplantation with fresh or 
cryopreserved human hepatocytes (huHep) via intrasplenic injection. Six to eight weeks after 
transplantation with human hepatocytes, large islands of human liver tissue are produced 
within the mouse liver, creating a mouse with a human/mouse chimeric liver [1]. The rate of 
successful engraftment in terms of huHep repopulation index (RI) is 60–70% as determined 
by calculating the human serum albumin levels.
The second mouse model that was developed had deficiency in the gene for the tyrosine cata-
bolic enzyme fumarylacetoacetate hydrolase (Fah). These Fah−/− mice could engraft their 
hepatocytes only in the presence of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione 
(NTBC) and lost the engrafted Hepupon drug removal. This gene deficiency was bred into 
immunodeficient mice to create the FRGN mouse [2]. The mouse also supported the develop-
ment of Plasmodium falciparum sporozoites into exoerythrocytic forms in the liver. Furthermore, 
when transplanted with human erythrocytes, they proved to be an effective model to study 
intraerythrocytic stages of P. falciparum.
1.2. TK-NOG mice for huHep transplantation
TK-NOG transgenic mouse in which mice express the herpes simplex virus thymidine kinase 
(HSVtk) transgenic construct containing the mouse albumin enhancer/promoter has drawn 
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significant attention. HSVtk mRNA is selectively expressed in the liver of NOG mice as a result 
of which they become prone to severe parenchymal liver damage after ganciclovir treatment
Of late, reconstitution of TK-NOG mice with human hepatocytes led to orthotopic de novo engraft-
ment and regeneration of huHep islands with controlled immunity and with broad repertoire. The host 
is prepared by creating liver stroma with ganciclovir and further reducing their nonadap-
tive immune responses by clo-lip treatment and deploying immunosuppression strategies 
through tacrolimus laden polymeric hydrogels, huHep transplantation in TK-NOG mice.
Prkdcscid (protein kinase, DNA-activated, catalytic polypeptide; severe combined immunode-
ficient mouse scid): Prkdc plays a crucial role in repairing double-stranded DNA breaks and in 
recombining the variable (V), diversity (D), and joining (J) segments of immunoglobulin and 
T-cell receptor genes.
Homozygous mutants do not have mature T and B cells, are not capable to evoke cell-mediated 
and humoral immune responses, and are supportive to allogeneic and xenogeneic grafts. These 
models therefore are useful cancer research models. The SCID mutation renders NOD mice 
diabetes-free and thereby makes them useful for adoptive transfer of diabetes through T cell. 
This mutation in CB17 mice could allow engraftment of human peripheral blood mononuclear 
cells (PBMC’s), fetal hematopoietic tissues, and hematopoietic stem cells (HSCs). The subopti-
mal engraftment efficiency and their inability to generate a potent and sizeable immune system 
are some of the striking limitations of this mouse model [3].
The above model proved to be unreliable because of the generation of mouse T and B 
cells, a phenomenon known as “leakiness,” and generation of high levels of host NK cells. 
Besides, SCID mice resulted in a defective DNA repair system which results in an increased 
radiosensitivity.
1.3. RAG1 and RAG2 mutation (recombination activating gene 1 and gene 2)
Targeted mutations at gene Rag1 and Rag2 loci prevent mature T-cell and B-cell develop-
ment in mouse but do not cause leakiness or radiosensitivity. Rag1 is essential for the V(D)J 
gene rearrangements that generate functional antigen receptors in T and B cells; homozygous 
Rag1tm1Mom mutants do not mature, functional T and B cells.
NOD-SCID mouse: This model is advantageous over others as it reportedly supported higher 
levels of engraftment of human PBMCs and showed lower NK-cell activity with additional 
defects in innate immunity. However, the use of this model has been limited because of the 
development of thymic lymphomas over the period of time and shorter life span thereby. 
The residual activity of NK cells and other components of innate immunity are some of the 
drawbacks of this mouse model
Mutation in (IL-2R) γ-chain: The IL-2Rγ-chain allows signaling through high-affinity recep-
tors such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The mutation in IL-2Rγ leads to devel-
opmental deficiencies in T cell, B cell, and NK cell. Also, this model supports engraftment 
of human tissues, HSCs and PBMCs. This model supported a remarkable decrease in the 
inflammation mediators (cytokines/chemokines), which, in turn, helped improve P.  falciparum 
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survival. IL-2Rγ mutation on NOD-SCID genetic background conferred an advantage that 
supported greater and high rising parasitemia which remains stable for weeks with greater 
reproducibility. Additionally, NSG mice shown lesser effect of aging which was due to the 
minimalized effect by interposition impact rendered by the IL-2Rγ mutation, along with a 
small sample size exhibiting marginal benefit of aging in the said mouse strain. The NSG-IV 
murine model when transplanted with human cells showed a great complementation of 
IL-2Rγ mutation byclo-lip treatment in controlling inflammation mounted by the cell engraft-
ment which reportedly showed the reduction in the erythrophagocytosis [1, 2, 4–7].
2. Liposomes: versatile carriers
Liposomes are small synthetic vesicles of spherical shape formulated from cholesterol and 
natural nontoxic phospholipids. The small size and hydrophobic and hydrophilic attributes of 
liposomes are some of the glaring features in addition to their biocompatibility and sustained 
release properties [8]. A liposome has an aqueous solution core surrounded by a hydrophobic 
membrane, in the form of a lipid bilayer, and therefore hydrophilic solutes dissolved in the 
core cannot readily pass through the bilayer [8].
The nature and attributes of liposomes vary depending upon the method employed for their 
formulation, lipid composition, and charge present on their surface. Moreover the choice of 
bilayer components determines the “rigidity” or “fluidity” and the charge of the bilayer [8]. 
For instance, unsaturated phosphatidylcholine species from natural sources (egg or soybean 
phosphatidylcholine) renders greater permeability with flexible stable bilayers, whereas the 
saturated phospholipids with long acyl chains (dipalmitoylphosphatidylcholine) form a rigid 
rather impermeable bilayer structure [8].
There has been experimental evidence on these phospholipids forming closed structures 
when mixed rigorously in aqueous phase [8]. These closed structures are hollow and there-
fore are used to deliver regardless of the nature of selected drug [8].
Hydrophobic chemicals are associated with the bilayer; lipid vesicles may be loaded with 
hydrophobic and/or hydrophilic molecules. The site-specific and controlled delivery of drugs/
candidate vaccines is achieved by the fusion of lipid bilayer with other bilayers such as the 
cell membrane. However, delivery of entrapped content through liposomal formulations is a 
complex and non-spontaneous phenomenon [8].
3. Advent of liposomes as delivery vehicle
The origin of liposomal formulation liposomes goes back to the mid-1960s, and when Alec D. 
Bangham and his coworkers discovered that phospholipids in the presence of suitable solvents 
form bilayer membranes which beget hollow spheres to form unilamellar or multilamellar 
vesicles (MLVs) [9]. The background is studied in three phase: “Origin,” “Medieval period,” 
and “Modern era.”
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Origin (1968–1975): The physiochemical characterization of liposomes had been carried out 
in this period. The approach of thin-film hydration was adopted for the development of mul-
tilamellar vesicles (MLVs). The closer resemblance to various biological membranes, lipo-
some, had been a natural choice to study the nature and functions of biological membranes; 
Bangham had called his lipid structures “multilamellar smectic mesophases” or sometimes 
“banghasomes” [9]. A more common term liposome was later coined by Weissmann [8].
Medieval period (1975–1985): Liposome’s utility was improved following basic research that 
increased the understanding of their stability and interaction characteristic within the system. 
There were methodological advancements; so far the formulation of liposomes was concerned 
further; the in-depth understanding on physiochemical properties of liposomes, their behav-
ior within the body, and their interaction with the cells led scientists to improve upon poten-
tial as drug carrier systems.
Modern era (1985 onward): Liposomes have been widely used all across the scientific disci-
plines including material sciences, mathematics, physics, biophysics, biochemistry, colloid 
science, and nanobiology for their well-bestowed delivery potential [9]. Ambisome, a paren-
teral amphotericin-B-based liposomal product, was initially synthesized along with numer-
ous products undergoing clinical trials or licensed for the market [9].
4. Classification of liposomes
The liposome size varies from very small (0.025 μm) to large (2.5 μm) vesicles comprising one 
or bilayer membranes. The circulation time of liposome is based on the size of the vesicle or 
in entrapment efficiency. The size and number of bilayers largely affect the amount of drug 
encapsulated in lipid vesicles, liposomes.
The bilayer behavior and size of liposomes provide an opportunity to categorize them as:
(a) Multilamellar vesicles (MLVs)
(b) Unilamellar vesicles: Unilamellar vesicles can also be classified into two categories: large 
unilamellar vesicles (LUVs) and [2] small unilamellar vesicles (SUVs). In unilamellar lipo-
somes, the vesicle is surrounded by a single phospholipid bilayer sphere keeping the aqueous 
solution bound inside it. In multilamellar liposomes, vesicles have a structure similar to that 
of an onion. The combination of several unilamellar vesicles will give rise to a multilamellar 
structure of concentric phospholipid separated by water layers [10].
1. Archeosomes: Archeosomes are vesicles derived from archaebacteria lipids. These are 
very different from the eukaryotic and prokaryotic bacteria. They are less sensitive to 
oxidative stress, high temperature, and alkaline pH [11, 12].
2. Cochleates: Cochleates are derived from liposomes, suspended in an aqueous two-phase 
polymer solution and are subjected to phase separation which allows appropriate parti-
tioning of polar molecule-based structures. When this solution is treated with cations like 
Ca2+ or Zn2, giving rise to cochleate precipitates less than 1 μm in dimension [13].
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3. Dendrosomes: Dendrosomes are a version of liposomes that along with being nontoxic 
are biodegradable, self-assembled, hyperbranched, dendritic, spheroidal nanoparticles 
which are easy to prepare, relatively cheap, and highly stable as well as easy to handle. 
The dendrosomes have proven for their delivery potential and hold an edge over existing 
synthetic vehicles for gene delivery. Dried reconstituted vesicles (DRV): This technique 
allows preparing small, “empty” unilamellar vesicles, containing different lipids or mix-
tures. Once SUVs are dissolved in solubilized drug, the dehydration is performed. The re-
hydration then leads to the formation of large quantities of heterogeneous multilamellar 
vesicles followed by further processing to form liposomal vesicles loaded with drugs [14].
4. Ethosomes: The ethosomes (the engineered liposomes) as compared to conventional li-
posomes have proven efficient so far the delivery attribute is concerned. Also, these car-
riers have reportedly known to show better entrapment of drug(s) [15]. Ethosomal drug 
permeation through the skin was demonstrated in diffusion cell experiments. Ethoso-
mal systems were composed of soy phosphatidylcholine, and about 30% of ethanol was 
shown to contain multilamellar vesicles by electron microscopy.
5. Immunoliposomes: Liposomes which are anchored with antibodies, Fabs, or peptide 
structures can be used in in vitro as well as in vivo applications [16, 17].
6. Immunosomes: The glycoprotein molecules attached onto the surface of preformulated 
liposomes are called “immunosomes.” The immunosomes do not vary in their appear-
ances with the prominent presence of spikes evenly distributed on their outer surface 
[18]. Immunosomes have structural and immunogenic characteristics closer to those of 
purified and inactivated viruses than any other forms of glycoprotein lipid arrangement.
7. Immune stimulating complex (ISCOM): ISCOMs are made up of saponin mixture Quil 
A, cholesterol, and phospholipids giving rise to spherical, micellar assemblies of about 
40 nm in size. They are constituted of amphiphilic antigens such as membrane proteins. 
ISCOMs have an inbuilt adjuvant Quillaja saponin, isolated from Quillaja [19].
8. Lipoplexes: Cationic lipid-DNA complexes, called Lipoplexes, are efficient carriers for 
cell transfection, but the rendered toxicity limits their applications [20, 21]. These local 
and systemic toxicities may result from either cationic lipids or nucleic acids.
9. LUVETs: Large unilamellar vesicles prepared by extrusion techniques (LUVETs) are 
chiefly performed with high-pressure systems. These proved to be more stable and did 
not cause leakage on treatment with detergents [22, 23].
10. Niosomes: Niosomes are small unilamellar vesicles made from nonionic surfactants also 
called novasomes. Their chemical stability is comparable to that of archeosomes [24, 25].
11. pH-sensitive liposomes: This class of liposomes is characterized as follows:
1. This class combines unsaturated phosphatidyl ethanolamine and acidic amphiphiles 
that render stability at neutral pH [26].
2. The second class compiles liposomes composed of lipid derivatives which gives in-
creased permeability to encapsulated solutes [26].
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3. The third class of pH-sensitive liposomes operates at low pH to destabilize mem-
branes. These are made of pH-sensitive peptides or fusion proteins [26].
4. The fourth class of liposome uses pH-sensitive liposomes and has pH-titrable poly-
mers to stabilize membranes which are susceptible to change in shape at low pH [26] 
(Figure 1).
12. Polymerized liposomes: Polymerized phosphatidyl choline vesicles (35–140 nm) have 
been synthesized from lipids bearing one or two methacrylate groups per monomer. 
These vesicles showed improved stability and controllable time-release properties com-
pared to non-polymeric analogs [27].
13. Proliposomes: Proliposomes (PLs) are defined as dry, free-flowing particles that immedi-
ately form a liposomal dispersion on contact with water. Proliposomes (PLs) are dry, free-
flowing granular products composed of drug(s) and phospholipid(s) which, upon addition 
Figure 1. Schematic representation of proposed mechanism of DNA immunization via endocytic pathway. Naked DNA is 
taken up by a small number of myocytes after i.m. injection, which are then transfected episomally. The produced antigen 
is released from the cells to interact with APC and thus induce immunity. In contrast, liposomal DNA interacts with APC 
directly and induces better immune response. It also protects DNA from degradation by deoxyribonuclease attack.
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of water, disperse to form a multilamellar liposomal suspension. These are  economically 
feasible to formulate and be used up to a great extent on commercial scale. These hydrated 
membranes form vesicles upon contact with water. Moreover, the distribution, transfer, 
and storage become easy due to their availability in lyophilized form [28–30].
14. Proteasomes: Vesicles of bacterial origin were solubilized followed by ammonium sul-
fate precipitation and dialysis against detergent buffer. Proteins and peptides are non- 
covalently complexed to the membrane making them highly immunogenic [31].
15. Reverse-phase evaporation vesicles (REVs): Vesicles are formed by evaporation of oil 
in water emulsions resulting in large unilamellar liposomes. The main problem encoun-
tered in the usage of organic solvents is its trace content even after evaporation in the final 
solution which can be hazardous to human health and also may affect the stability of the 
vesicles. However, this issue may be addressed by the use of polycarbonate filters which 
allowed the separation based on their size and entrapment efficiency. Furthermore, as 
an alternative, diethyl ether can also be used as an organic solvent because of its lesser 
 toxicity [32, 33].
16. Stealth liposomes: When liposomes are modified by coating them with polyethylene 
glycol (PEG), a synthetic hydrophilic polymer can greatly induce stability and their cir-
culation half-life. These advantages have established glycolipids for surface anchoring in 
order to achieving targeted and sustained delivery. The engineering process of this class 
of liposome culminated with the observation that coating of liposomes with polyethyl-
ene glycol (PEG), a synthetic hydrophilic polymer, would improve their stability and 
lengthen their half-lives in circulation, rendering the use of glycolipids obsolete [34–38].
The PEG coating stabilizing effect arises from high concentration of hydrated groups that 
inhibit both hydrophobic and electrostatic interactions of variety of blood components 
and thereby limits their recognition by the reticuloendothelial system (RES) [39, 40].
17. Temperature-sensitive liposomes: Temperature-sensitive liposomes permit easy gel to 
liquid crystallization phase transition above the physiological temperatures and are 
efficient in achieving target-specific drug delivery. This property is achieved by the us-
age of thermosensitive polymers [41], and therefore, content release, surface properties, 
and their cell-surface binding may be controlled by the temperature [42].
18. Transfersomes: Transfersomes formulated by phosphatidylcholine and cholate are 
highly deformable making them as preferred choice for transcutaneous delivery of drugs 
and candidate vaccines. This in contrast to conventional liposomes and niosomes offers 
needle-free delivery of vaccines and an increased concentration of antibody titer which 
may suffice the need of systemic and mucosal immunity by provoking humoral and cell-
mediated branches of immune system. Moreover, these ultra-deformable carriers can eas-
ily overcome the skin barrier and efficiently deliver the antigenic payload [43, 44].
19. Virosomes: Virosomes are small unilamellar vesicles containing influenza hemaggluti-
nin, by which they became fusogenic with endocytic membranes. The co-incorporation of 
other membrane antigens induces enhanced immune responses [10, 45].
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5. Engineered version of liposomes
A greater population has relied on the use of antibiotics. However, emergence of resistance 
against antibiotics has warranted a demand to identify a new class of antibiotics with an effi-
cient mode of delivery.
The scientists engineered an artificial nanoparticles made of lipids, “liposomes,” that closely 
resemble the membrane of host cell which target bacterial toxin [46]. Since bacteria are not tar-
geted directly, the liposomes do not promote the development of bacterial resistance. In clini-
cal medicine, liposomes are used widely as a vehicle to deliver specific medication into the 
body for achieving extended release [46]. The liposomal formulation, however, act as traps 
for bacterial toxins, sequesters, and neutralizes them instantly which would be subsequently 
eliminated by the host’s own immune system.
6. Role of clodronate-loaded liposome in global immunosuppression
Clodronate (dichloromethylene bisphosphonate) is a nontoxic drug but impermeable to cell 
membrane. However, liposomes prepared by using phosphatidylcholine and cholesterol are 
not toxic and are engulfed by wandering macrophages. The hydrophobic drug clodronate 
when administered naked will be cleared from the circulation and gets absorbed by the diges-
tive system and may face the leakiness issue. However, when administered through lipo-
somes, it would not easily escape from the cell and is retained [47].
It is evident that clodronate may be delivered into phagocytic cells using liposomes as vehi-
cles, therefore preventing it from being escaped from the cell [47].
The cell enzyme lysosomal phospholipases disrupt the phospholipid layer of liposome and 
induce release of drug clodronate which gets accumulated sizably within the cell. The free 
clodronate has an extremely short half-life in the circulation and is cleared from the circu-
lation by the renal system. Therefore, specific entrapment of clo-lip formulation by macro-
phages induces selective apoptosis of macrophages. Therefore, a technique that involves 
the macrophage “suicide” approach, using the liposome-mediated intracellular delivery of 
dichloromethylene bisphosphonate (CI2MBP or clodronate) was deployed. The method is 
specific with respect to phagocytic cells of the mononuclear phagocyte system (MPS) [47].
7. Autoimmune hemolytic anemia (AIHA) liposome
Autoimmune hemolytic anemia is a disease in which autoantibodies against RBCs lead to 
their premature destruction. The autoantibodies of the IgG type lead primarily to the uptake 
and destruction of RBCs by splenic and hepatic macrophages. The current therapies such as 
corticosteroids and splenectomy are directed at interfering with this process. Clodronate-
loaded liposomes (dichloromethylene diphosphonate) selectively deplete  macrophages 
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within 24 h of administration by inducing apoptosis of macrophages. Therefore, liposomal 
clodronate would be a useful agent for treating sAIHA. This drug formulation was effective 
within hours by first blocking and then depleting phagocytic macrophages, and its action 
lasted for 3–4 days in vivo. Thus, in AIHA, liposomal clodronate therapy may act like a 
temporary, medicinal splenectomy. Therefore, clo-lip treatment may prove useful in situa-
tions where rapid response to therapy is critical or other medical therapies are inadequate.
Clodronate-loaded liposomes completely halted the uptake of opsonized RBCs by the spleen 
in contrast to splenectomy which used corticosteroid treatment. However, this cannot replace 
the corticosteroid treatment but offers an advantage because the spleen is not removed, and 
its function is eventually restored by the natural replenishment of macrophages. Clodronate-
loaded liposomes undertaken in this treatment are temporary but are spontaneous in treating 
AIHA as compared to corticosteroids.
8. Immunosuppression by liposome-mediated delivery of specific drugs
Normally, liposomes are now known for immunosuppression. However, liposome loaded 
with cytostatic drugs for cancer therapeutics is reported to cause more or less immune sup-
pression [48]. These drug-loaded formulations opened new avenues in cancer immuno- 
therapeutics.
The doxorubicin, an anticancer drug, commercially sold as doxil (a liposomal formulation) 
when administered in vivo, showed macrophage suppression. The immunosuppression was 
seen from the long-lived persistence of bacteria in the blood stream. We have tried immuno-
modulatory and pharmacological reagents/chemicals which were used to further suppress 
the residual innate immune response (Table 1) [47–50] of huRBC reconstituted immunode-
ficient mouse (huRBC-NSG) for the engraftment and survival of P. falciparum. Also, immu-
nosuppression of nonadaptive residual immune responses of immunodeficient mouse was 
contained by clodronate-loaded liposomes in order to achieving significant huRBC grating in 
immunodeficient animals (NSG) (Figure 2).
8.1. Adjuvanticity of liposomes
When bestowed along with clodronate, EDTA, DTPA, or various calcium or metal ion com-
plexes of these chelators have the potential to deplete macrophages in vivo. Liposomal formu-
lations have reportedly enhanced the immune response both at humoral and cell mediated 
of a vaccine formulation [44, 51]. The adjuvant action of liposomes may be categorized as:
1. The marginal zone antigens of macrophages residing inside the spleen can be targeted 
through liposomes.
2. The liposomes are used to block or deplete the activity of suppressor alveolar macrophages.
Thus, liposomes offer the advantage of both drug administration and adjuvant [51, 52].
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Protocol tested Dose No. of mouse % success  
(more than 2 days)
Parasitemia length  
average (days)
Best parasitemia  
(days)
DMSO 5% 18 88.8 7.18 12
TGFβ 100 ng/day 17 23.5 7.25 8
1 μg/day 3 66.6 10 13
Splenectomy 5 60 7 10
Cyclophopshamide 75 mg/kg 7 100 7.6 9
50 mg/kg 12 41.6 6.8 9
Coinfection P. chabaudi P. falciparum 7 71.42 11 24
Coinfection P. yoelii P. falciparum 52 90.24 11.09 34
NAC 100 mg/kg 25 56 11.07 19
Vitamin E 20 mg/kg 13 77 8.25 34
Trolox 4 mg/kg 5 60 3.85 6
Anti-NK (TMβ-1) 1 mg 15 53.3 4.12 8
Futhan 20 μg/day 4 50 2.75 4
Bleeding 20 35 7.42 14
P. falciparum various amount 0.3% 2 100 2 2
1% 2 100 4 4
5% 2 100 5.5 6
7% 2 100 4 4
10% 2 100 5.5 6
pABA 400 mg/kg 4 100 4.5 5
Folinic acid 400 mg/kg 4 100 4.5 5
Table 1. Coinfection of Plasmodium chabaudi and Plasmodium yoelii; NAC and vitamin E seem to have beneficial effect in P. falciparum survival; however, results are very 
heterogenous from one mouse to other and from one experiment to other [5].
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9. Clodronate-loaded liposomes play a crucial role in host’s 
immunosuppression for sizeable P. falciparum grafting in a 
humanized mouse
To aid in human cell engraftment in recently developed transgenic/immunodeficient 
strain, TK-NOG [53] mouse is used. Clodronate-loaded liposome will ameliorate the 
residual nonadaptive immune response by depleting the sizeable number of cells from 
monocyte-macrophage lineage. The clo-lip (clodronate-loaded liposome) is scavenged by 
the cells of monocyte-macrophage lineage, triggering their apoptosis and creating stroma 
for huHep grafting. Recent surge in the usage of humanized mouse models owing to the 
results from earlier findings [4, 5] in which clodronate-loaded liposome treatment depletes 
Figure 2. Immunosuppression of nonadaptive residual immune responses of immunodeficient mice by the sustained 
delivery of (a) clodronate via liposomes and (b) chemical immunomodulation protocol to control residual innate 
immune responses for robust “humanization”.
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the macrophage level in an immunodeficient mouse (Pf-NSG-IV) to study of asexual blood 
stage infection of P. falciparum (Figures 2 and 3).
10. Human malaria: a systemic inflammatory infectious disease
Malaria is one of the most deadly diseases in terms of mortality and morbidity affecting almost 
2 million people worldwide. According to the WHO report, 2015, mortality due to malaria 
reached 438,000 deaths worldwide, majority of these occurring in African region (90%), fol-
lowed by the Southeast Asia region (7%) and the Eastern Mediterranean region (2%).
However the malaria incidents dropped drastically by 37% across the globe and by 42% in 
Africa. Also there was a gradual decrease in the mortality rate by 60% globally and 66% in 
African region. The life cycle of malaria parasite is shown in Figure 4.
P. falciparum has gone to a wider trajectory to develop resistance against all the drugs and 
more complex patterns of multidrug resistance than anticipated. The suboptimal and uncon-
trolled use of drugs may lead to severe consequences of drug resistance in the field which 
could pose threat with unprecedented global health crisis. This scenario gets dangerous in the 
wake of unavailability of effective vaccines against P. falciparum.
10.1. The malaria vaccine development: a challenging task
Malaria is actually caused by the parasite called Plasmodia spp. which is highly evolved and a complex 
organism. The mercurial behavior of parasite because of the secretion of tens of thousands of proteins 
Figure 3. P. falciparum engraftment and development in an optimized humanized (PfhuRBC/NSG-IV) mouse [4, 5, 48]. A) 
Upper panel shows significant human blood chimerism in NSG mice over the period of more than 21 days, and B) lower 
panel illustrates the sizeable parasitemia using three (PAM, 3D7 and K1) P. falciparum strains in the huRBC reconstituted 
NSG mice.
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at each and every stage establishes it as one of the biggest challenges of humanity. The classical way of 
making a vaccine is to take the whole organism, the whole bacterium, or the virus and to inactivate it 
and to inject that as vaccine. That can be done for malaria, but it has been very hard to deploy that into 
a product—it is actually even harder to cultivate parasite especially liver stage in the lab as the condi-
tions are not commensurate for its replication. The induction of potent and sterile immune responses 
is very difficult against LS of P. falciparum.
Parasite undergoes liver-stage development culminating in the formation and release of tens 
of thousands of first-generation parasites going undetected as this stage is asymptomatic. 
The asexual parasite stage can be cultivated in vitro, but the sporogonic stages require a work-
able humanized mouse model.
The P. falciparum consists of about 23 megabase nuclear genomes which has 14 chromo-
somes and encodes about 5300 genes. For example, two genes mainly Pfmdr1 and Pfmdr2 
(Plasmodium falciparum multidrug resistance), Plasmodium falciparum multidrug resistance-
associated protein (Pfmrp), are linked with the amount of drug that accumulates inside the 
digestive vacuole. Efficacy of drugs is dependent on these transporters as they shuffle them 
from intravacuolar to extravacuolar and vice versa. This observation suggests the common 
element of multigenic mechanism associated with mefloquine, halofantrine, and dihydroar-
temisinin. As the same gene has different effects depending on the type of gene mutation, it 
becomes difficult to identify any one functional gene emanating resistance. Therefore, vaccine 
development is a challenging and a herculean task to achieve [54].
Figure 4. Life cycle of malaria parasite.
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11. Liposome as a vaccine candidate
Liposomes are tools that can be used in tumor-targeting, gene-silencing, antisense therapy; 
immunomodulation; and genetic vaccination [48]. Liposomes (pH-sensitive liposomes) are 
majorly used for targeted and cytosolic delivery of vaccine candidate for achieving perdurable 
immune responses as well as delivery of drugs. They can be used as an efficient tool in vaccine 
development. The mycobacterial lipids when used to formulate liposomes have shown immense 
potential for mounting upon the sizeable cellular response which are considered as Th1 adjuvant.
The 19 kDa fragment (carboxy-terminal) of merozoite surface protein-1 of Plasmodium 
falciparum (PfMSP-119) is delivered directly into the cytosol with the help of liposomes 
to enhance immunogenicity. Engineered liposomes are used for sustained release of 
entrapped content and to increase immunogenicity. The liposomal vesicles have entrapped 
core of polymer that provides mechanical strength to them.
Gel core liposomes (engineered liposomes) were potentially tested for their utility in intra-
muscular delivery of transmission blocking antigen Pfs25 (recombinant protein antigen). 
Further, by using these engineered liposomes, the study evaluated the effect of coadministra-
tion of vaccine adjuvants CpG-ODN on the immune system of Pfs25. Liposome formulations 
of caryostatics, antibiotics, photosensitizers, enzymes, hormones, cytokines, and nucleic acids 
are being used to achieving some very promising results.
For targeting the DNA vaccine uptake and expression, APC are a preferred alternative to 
muscle cells. Antigen-coding plasmid DNA when administered via liposomes could bypass 
the need of muscle involvement and facilitates its uptake by APC, for instance, those infil-
trating the site of injection or in the lymphatic, at the same time protecting DNA from 
nuclease attack [48, 55]. Engineered liposomes show advantage because of their evasion 
ability to escape the invasive route of administration making it an efficient carrier for the 
delivery of entrapped contents. Transfection of APC with liposome-entrapped DNA could 
be rendered by selecting an appropriate vesicle surface charge and lipid composition or by 
the co-entrapment of other adjuvants together with the plasmid DNA [48, 55–58] (Figure 5).
The proposed concepts of antimalarial vaccine based on liposomal construct of various types 
(cocktail formulation):
a. Recombinant protein-containing liposomes target specific, however, non-pH sensitive to 
deliver rDNA protein from (CSP 22), SPF 66 form of sporozoites and merozoites, so that 
proteins are specifically processed through endosomal pathway and presented by APCs 
through MHC II.
b. The second population of liposomes will contain dendritic cells targeted pH-sensitive 
liposomes bearing rDNA lipid complexes (target specific and pH sensitive) to deliver 
them to the cytosol of specific cells, that is, dendritic cells for subsequent expression of 
liver-stage and erythrocytic stage antigenic cellular expression and MHC I restricted pres-
entation for Th-1 cellular CTL responses.
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12. Cytotoxicity rendered by liposomes
1. Dermal toxicity: Conventional doxorubicin is used actively in various malignant tumors 
giving rise to a number of side effects like cardiotoxicity and myelosuppression. A differ-
ent approach of this chemotherapeutic agent enclosed in PEGylated liposomes, in which 
liposome encapsulation prevents doxorubicin from penetration to compartments with 
tight endothelial cells junctions and facilitates its distribution to tissues with abnormal 
blood vessels [59]. This results in higher drug accumulation within the tumor than normal 
tissues. Consequently, a decreased incidence of cardiac and hematological toxicity is ob-
served. PEGylated liposomal doxorubicin (PLD) has the ability to deposit itself within the 
skin and to induce specific mucocutaneous reactions. There are six types of PLD-related 
dermal disorders, and the most common is palmar-plantar erythrodysesthesia (PPE) [60]. 
Other less frequent manifestations are intertrigo-like dermatitis, a diffuse follicular rash, 
a maculopapular rash, melanotic macules, or a recall phenomenon. Dermal toxicity is the 
most common adverse reaction limiting PLD therapy. Skin lesions usually appear in re-
gions prone to trauma such as the palms and soles. This was reported in a patient suffering 
from ovarian cancer showing partial response to chemotherapy [61].
2. PEGylated liposomal doxorubicin (PLD) was administered in patients. These PEGylated li-
posomes show a lower rate of cardiotoxicity and myelosuppression but show some  obvious 
adverse effects including palmar-plantar erythrodysesthesia (PPE and some dermal 
manifestations such as intertrigo-like dermatitis, diffuse follicular rash, melanotic macules, 
Figure 5. Schematics illustrating the proposed concepts of antimalarial vaccine based on liposomal construct of various 
types (cocktail formulation).
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maculopapular rash [61]. Some studies have advocated that dimethyl sulfoxide or corticos-
teroids may be beneficial in the treatment of PLD-induced dermal complications as they 
accelerate skin recovery. The only well-established preventive management includes dose 
intensity modification or complete chemotherapy discontinuation.
13. Future challenges
For some drugs like DaunoXome, AmBisome, Doxil, Epaxel, etc., liposomes have proved to be 
a reliable delivery vehicle with some major challenges:
1. Uptake by reticuloendothelial system: Liposomes may be formulated as aerosol and as 
semisolid form such as cream, gel, or dry powder and are administered. They will then 
be readily taken up by the mononuclear phagocyte system (MPS) such as Kupffer cells of 
the liver and spleen. This is the natural route for the uptake of liposomes; however, they 
lack the ability to target site-specific receptors expressed on the surface of diseased cells 
and hence are inefficient for site-specific delivery. Therefore, liposomes which may evade 
rapid uptake by MPS need to be developed and further explored. PEG-coated or sterically 
stabilized liposomes are a few glaring examples.
2. Large-scale production: Production of liposomes from small scale (laboratories) to a large 
scale is a challenging task. The regulatory norms of the use of chloroform and methanol 
are not recommended more than the permissible limits. Preparation of liposomes also in-
volves various steps like evaporation of solvent system under reduced pressure, prepara-
tion of thin lipid film, sonication, etc. These procedural hurdles pose a challenge across the 
researchers to develop these vehicles on a large scale.
3. In process stability: The oxidation and/or hydrolysis of phospholipids used in liposomal 
preparation does not allow the long-term storage and therefore less shelf-life. The physi-
cal and chemical instability of prepared liposomes is something to be explored further. 
However, fewer formulations are used in a lyophilized form which is to be reconstituted 
in a suitable buffer before use. Also, liposomes cannot withstand the degradation from 
proteins and enzymes in an animal model due to electrostatic stabilization.
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